These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17596576)

  • 1. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
    Moinpour CM; Darke AK; Donaldson GW; Thompson IM; Langley C; Ankerst DP; Patrick DL; Ware JE; Ganz PA; Shumaker SA; Lippman SM; Coltman CA
    J Natl Cancer Inst; 2007 Jul; 99(13):1025-35. PubMed ID: 17596576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of the Prostate Cancer Prevention Trial (PCPT).
    Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
    Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality-of-life findings for the prostate cancer prevention trial.
    Moinpour CM; Darke AK; Donaldson GW; Cespedes D; Johnson CR; Ganz PA; Patrick DL; Ware JE; Shumaker SA; Meyskens FL; Thompson IM
    J Natl Cancer Inst; 2012 Sep; 104(18):1373-85. PubMed ID: 22972968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH; Meehan A; Lee M; Penson DF; Wessells H
    J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.
    Song Y; Tangen C; Goodman P; Parnes HL; Lucia MS; Thompson IM; Kristal AR
    Prostate; 2008 Feb; 68(3):281-6. PubMed ID: 18163420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
    Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
    J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.
    Fujita K; Landis P; McNeil BK; Pavlovich CP
    J Urol; 2009 Dec; 182(6):2664-9. PubMed ID: 19836757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
    Giuliano F; Rubio-Aurioles E; Kennelly M; Montorsi F; Kim ED; Finkbeiner AE; Pommerville PJ; Colopy MW; Wachs BH;
    Spine (Phila Pa 1976); 2008 Apr; 33(7):709-15. PubMed ID: 18379396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study.
    Dinsmore WW; Wyllie MG
    BJU Int; 2009 Apr; 103(7):940-9. PubMed ID: 19245438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.